Targepeutics, Inc. Announces New Approaches to Brain Tumor Therapy Consortium (NABTT) Relationship
Posted on: Monday, 12 December 2005, 09:00 CST
HERSHEY, Pa., Dec. 12 /PRNewswire/ -- Targepeutics presented at the semi-annual New Approaches to Brain Tumor Therapy Consortium (NABTT) business meeting held in Philadelphia on December 1, 2005. Targepeutics is planning to conduct a Phase I clinical trial for high-grade glioma with this group of top medical institutions in early 2007.
Targepeutics' lead compound, Glioblast-13, is the more specific, second generation technology to the current IL-13PE38QQR compound (wildtype IL-13) that is currently in Phase III clinical trials. Glioblast-13 is a patented, mutated form of Interleukin-13 that specifically targets receptors on brain cancer cells while sparing the normal cells that do not express the target.
With NABTT's heavy involvement and using its experience from past trials, the clinical protocol for Glioblast-13 is near completion for presentation to the FDA in an upcoming pre-IND meeting with the Agency the first quarter of 2006.
Targepeutics is a biopharmaceutical company developing selective molecularly targeted therapeutics to fight cancer. Currently, Targepeutics' three pharmaceutical platforms are Targepeutics' Genetically Engineered Interleukin-13, Immunotherapy (applications in cancer and asthma), and Anti- tumor Progression (targeting growth and ability of solid tumors to create new blood vessels). Targepeutics is based in Hershey, Pennsylvania and is privately held.
For more information, please contact: Sil Lutkewitte, President, at slutkewitte@targepeutics.com.
Targepeutics, Inc.
CONTACT: Sil Lutkewitte, President, Targepeutics, Inc.,slutkewitte@targepeutics.com
Web site: http://www.targepeutics.com/
Source: PRNewswire
Related Articles
- Whistleblower Retaliation Lawsuit Filed Against Carle Cancer Doctors and Executives in Connection with Violations of the Federal Safety Laws Protecting Patients in Experimental Clinical Cancer Trials
- NCI Renews Mayo Clinic Cancer Center Support Grant, Extends Comprehensive Status
- Rexinoid Developed By NuRx Pharmaceuticals Shows Promise in Prevention, Treatment of Lung, Breast Cancer, Paper in Clinical Cancer Research Reports
- Enzon's PEG-SN38 Featured in Clinical Cancer Research
- Novacea's Proof-of-Principle Study of AQ4N in Solid Tumors Published in Clinical Cancer Research
- Mayo Clinic Cancer Prevention Study Begins
- Clinical Cancer Research Publishes Paper Comparing CTCs to Imaging in Predicting Overall Survival in Metastatic Breast Cancer
- Application of Sentinel Principle in Bladder Cancer Published in Clinical Cancer Research
- Data in Clinical Cancer Research Article Shows That Peregrine's Lead VEA Compound Enhances Efficacy of Multiple Chemotherapeutic Agents
- 'Clinical Cancer Research' Article States Tarvacin(TM) Equivalent Inhibits Tumor Growth By Up to 90% in Multiple Tumor Models
 |
 |
User Comments (0)
RSS Feeds